# Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

> **NCT05624840** · — · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 85 (actual)

## Conditions studied

- COVID-19
- Chronic Kidney Disease stage4
- Chronc Kidney Disease Stage 5

## Interventions

- **DRUG:** Nirmatrelvir/ritonavir

## Key facts

- **NCT ID:** NCT05624840
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-02-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624840, "Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05624840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*